PRV211 (Intraoperative Cisplatin System)
Small molecule
PRV211 (Intraoperative Cisplatin System) is one of 30 small molecule programs targeting Oral Squamous Cell Carcinoma. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Oral Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Aldara
BBausch Health Americas, Inc.
Approved
Glucophage
EMD SeronoApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
One-Alpha
RochePhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Beyfortus
BeiGenePhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Tuoyi
SSun Yat-sen University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- PPrivo Technologies